Tasquinimod

Overview

Tasquinimod is an oral S100A9 inhibitor being evaluated in multiple myeloma.

SparkCures ID 382
Developed By Active Biotech AB
Generic Name Tasquinimod
Additional Names ABR-215050, CID 54682876
Treatment Classifications
  • S100A9 Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources